MUC13抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using MUC13 mouse mAb against HT-19 (1), SW620 (2), and NIH/3T3 (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of RSC-96 cells using MUC13 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human colon cancer tissues using MUC13 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectal cancer tissues using MUC13 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rat thyroid tissues using MUC13 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rabbit lymph node tissues using MUC13 mouse mAb with DAB staining.    

  
  

The MUC13 antibody targets the MUC13 glycoprotein, a member of the transmembrane mucin family. MUC13 is characterized by its large extracellular domain containing tandem repeats rich in serine, threonine, and proline residues, a transmembrane region, and a cytoplasmic tail with signaling motifs. Primarily expressed in epithelial tissues, particularly the gastrointestinal tract, MUC13 plays roles in cell adhesion, signaling, and mucosal protection. Dysregulation of MUC13 has been linked to pathologies, especially cancers. Overexpression is observed in colorectal, gastric, pancreatic, and ovarian cancers, where it promotes tumorigenesis by enhancing proliferation, metastasis, and chemoresistance through interactions with HER2. PKC, and NF-κB pathways.

MUC13 antibodies, both monoclonal and polyclonal, are critical tools for research and diagnostics. They enable detection of MUC13 expression via immunohistochemistry, Western blotting, and flow cytometry, aiding in cancer profiling and biomarker studies. Therapeutically, MUC13-targeting antibodies are under investigation for antibody-drug conjugates (ADCs) or immune checkpoint blockers, exploiting its cancer-specific overexpression. Challenges include ensuring antibody specificity due to structural similarities among mucins and optimizing delivery in vivo. Current research also explores MUC13's role in immune modulation, as its extracellular domain may interact with immune cells in the tumor microenvironment. Further development of MUC13 antibodies could advance precision oncology and improve diagnostic accuracy for mucin-associated malignancies.